Since PPARα and PPARγ are differentially expressed in the kidneys, it is reasonable that these two effectors play opposing roles in tubular cell CaOx crystal deposition and should be considered when treating MetS patients with kidney stones. Here, PPARA is linked to nephrolithiasis.